CStone reports 87.5% response rate for CS2009 in first-line PD-L1-high lung cancer

• CStone Pharmaceuticals reported CS2009 clinical results from more than 300 patients, presented at the European Society for Medical Oncology Congress 2026.
• The investigational antibody showed antitumor activity in lung and colorectal cancers, including heavily pretreated patients, as monotherapy or combined with chemotherapy.
• Safety findings showed manageable tolerability, with no new safety signals identified in the lung and colorectal cancer cohorts.
• Global Phase III registration trials are planned to begin by the end of 2026, supported by the accumulating clinical data.
• Discussions with multinational pharmaceutical companies are underway for potential partnerships to accelerate global development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261025-12382331), on October 25, 2026, and is solely responsible for the information contained therein.